Skip to main content
Fig. 1 | Cancer Nanotechnology

Fig. 1

From: Radiolabeling and PET–MRI microdosing of the experimental cancer therapeutic, MN-anti-miR10b, demonstrates delivery to metastatic lesions in a murine model of metastatic breast cancer

Fig. 1

Characterization of nat/64Cu-MN-anti-miR10b. a Radiochemical purity confirmed by iTLC. (Top) unlabeled Cu-64, (middle) separation of 64Cu-MN-anti-miR10b and unlabeled Cu-64, and (bottom) 64Cu-MN-anti-miR10b after PD-10 purification. b HPLC traces of 64Cu-MN-anti-miR10b using size exclusion chromatography, (top) UV trace at 254 nm, (Bottom) radiodetector. c TEM of Cu-MN-anti-miR10b and natCu-MN-anti-miR10b. d Nanoparticle size by TEM and DLS. e In vitro cell uptake by breast adenocarcinoma cells. f qRT-PCR demonstrating target engagement (inhibition of miR-10b). natCu was utilized for the preparation of natCu-MN-anti-miR10b (t-test, n = 3, **P < 0.01)

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us